COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0BR8X
|
|||
Drug Name |
PUL-042
|
|||
Synonyms |
ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042
|
|||
Drug Type |
Protein/peptide drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN toll-like receptor 2 (TLR2) | Target Info | Agonist | [2], [3] |
PUL-042 is a novel combination of two synthetic molecules (Pam2 and ODN) that are agonists of Toll-like receptors. Pam2CSK4 acetate (Pam2), a synthetic diacylated lipopeptide (LP) that is an agonist of TLR2 and TLR6 (TLR2/6) and the TLR9 agonist oligodeoxynucleotide (ODN) M362, which contains unmethylated CpG-based dinucleotides, with potential immunostimulating activity. By stimulating these receptors on lung epithelial cells, PUL-042 initiates an innate immune system response that better protects the body from SARS-CoV-2 infections | ||||
HUMAN toll-like receptor 6 (TLR6) | Target Info | Agonist | [2], [3] | |
PUL-042 is a novel combination of two synthetic molecules (Pam2 and ODN) that are agonists of Toll-like receptors. Pam2CSK4 acetate (Pam2), a synthetic diacylated lipopeptide (LP) that is an agonist of TLR2 and TLR6 (TLR2/6) and the TLR9 agonist oligodeoxynucleotide (ODN) M362, which contains unmethylated CpG-based dinucleotides, with potential immunostimulating activity. By stimulating these receptors on lung epithelial cells, PUL-042 initiates an innate immune system response that better protects the body from SARS-CoV-2 infections | ||||
HUMAN toll-like receptor 9 (TLR9) | Target Info | Agonist | [2], [3] | |
PUL-042 is a novel combination of two synthetic molecules (Pam2 and ODN) that are agonists of Toll-like receptors. Pam2CSK4 acetate (Pam2), a synthetic diacylated lipopeptide (LP) that is an agonist of TLR2 and TLR6 (TLR2/6) and the TLR9 agonist oligodeoxynucleotide (ODN) M362, which contains unmethylated CpG-based dinucleotides, with potential immunostimulating activity. By stimulating these receptors on lung epithelial cells, PUL-042 initiates an innate immune system response that better protects the body from SARS-CoV-2 infections |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04312997) The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. U.S. National Institutes of Health. | |||
2 | Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. | |||
3 | TLR 2/6/9 agonist PUL-042 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.